- cafead   Jun 24, 2024 at 11:12: AM
via Novo Nordisk has shared a closer look at phase 3 results on its hemophilia A candidate Mim8, revealing new data that show how it squares up against Roche’s blockbuster Hemlibra on key measures of efficacy and tolerability.
article source
article source